Cargando…

752. Management of 20 Patients Diagnosed with Posaconazole-Induced Pseudohyperaldosteronism

BACKGROUND: Posaconazole-induced pseudohyperaldosteronism (PIPH) has been associated with elevated posaconazole serum concentrations. Clinicians are faced with the difficult task of managing patients with PIPH while not compromising the efficacy of antifungal prophylaxis or treatment. Commonly, modi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gintjee, Thomas J, Davis, Matthew R, Nguyen, Minh-Vu Hoang, Young, Brian, Odermatt, Alex, Thompson, George R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776591/ http://dx.doi.org/10.1093/ofid/ofaa439.942

Ejemplares similares

732. Posaconazole Serum Drug Levels Associated with Pseudohyperaldosteronism
por: Nguyen, Minh-Vu Hoang, et al.
Publicado: (2019)

Severe Posaconazole-Induced Glucocorticoid Deficiency with Concurrent Pseudohyperaldosteronism: An Unfortunate Two-for-One Special
por: Villar-Prados, Alejandro, et al.
Publicado: (2021)

ODP442 Posaconazole-induced Pseudohyperaldosteronism (PIPH) in Patient Treated for Acute Myeloid Leukemia
por: Shrestha, Bishow, et al.
Publicado: (2022)

752. Costs Attributable to Clostridioides difficile Infection in the Presence of Differential Mortality
por: Sahrmann, John, et al.
Publicado: (2021)

Gynecomastia and hypertension in a patient treated with posaconazole
por: Thompson, George R., et al.
Publicado: (2020)

Licorice: From Pseudohyperaldosteronism to Therapeutic Uses
por: Sabbadin, Chiara, et al.
Publicado: (2019)

Posaconazole-Induced Hypertension and Hypokalemia: Mechanistic Evaluation
por: Thompson, George R, et al.
Publicado: (2017)

752. Decreased Echinocandin Resistance among Candida glabrata over an Eleven-Year Period at a University Hospital
por: Raabe, Nathan, et al.
Publicado: (2022)

Licorice induced pseudohyperaldosteronism, severe hypertension, and long QT
por: Smedegaard, Stine Bech, et al.
Publicado: (2019)

Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2
por: Thompson, George R, et al.
Publicado: (2019)

752. Geographic Analysis of Latent Tuberculosis Screening: A Health System Approach
por: Bonnewell, John, et al.
Publicado: (2018)

169. AT-752, an Oral Guanosine Nucleotide Prodrug, Exhibits Potent in Vitro Activity Against Flaviviruses and Prevents Disease Progression in a Dengue Mouse Model
por: Good, Steven S, et al.
Publicado: (2020)

752. Timing of Antibiotics Administration in Emergency Department and Mortality in Sepsis by Sepsis-3 Definition
por: Seok, Hyeri, et al.
Publicado: (2019)

1148. Activity of Posaconazole and Comparator Antifungal agents Tested Against Filamentous Fungi
por: Castanheira, Mariana, et al.
Publicado: (2020)

752 Assessment of Aminoglycoside Dosing at a Large Academic Medical Center
por: Ghamrawi, Riane, et al.
Publicado: (2014)

1161. Effectiveness of Posaconazole in the Treatment of Rare Invasive Fungal Infections: A Systematic Literature Review
por: Bernauer, Mark, et al.
Publicado: (2020)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

A Case of Pseudohyperaldosteronism Induced by Yokukansan and Shakuyakukanzoto That Resulted in Severe Hypokalemia
por: Arai, Mika, et al.
Publicado: (2023)

974. Real World Experience of Posaconazole Therapeutic Drug Monitoring in Oncology Patients: Clinical Implications of Hypoalbuminemia as a Predictor of Subtherapeutic Posaconazole Levels
por: Pasikhova, Yanina, et al.
Publicado: (2023)

752. Development of an Outpatient Infectious Disease Rotation for Internal Medicine Residents at a Rural Academic Medical Center
por: Bryan, Nicole, et al.
Publicado: (2023)

P752: TRANSCRIPTOMIC ANALYSIS OF MYELOID-DERIVED SUPPRESSOR CELLS (MDSCS) IN THE PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA (CIN)
por: Bizymi, Nikoleta, et al.
Publicado: (2023)

1169. In Vitro Activity of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Enrolled in a Clinical Trial
por: Castanheira, Mariana, et al.
Publicado: (2020)

411. Tolerability of Isavuconazole After Posaconazole Toxicity in Leukemia Patients
por: DiPippo, Adam J, et al.
Publicado: (2018)

Therapeutic Drug Monitoring (TDM) of Suspension (SUS), Extended-Release (ER), and Intravenous (IV) Posaconazole (POS) at a Large Transplant Center
por: Haidar, Ghady, et al.
Publicado: (2017)

941. Isavuconazole Prophylaxis Against Invasive Fungal Infection: A Pooled Analysis with a Comparison of Posaconazole Delayed-release Tablet Prophylaxis
por: Lee, Chaeryoung, et al.
Publicado: (2021)

1703. Hematologic Toxicity of Valganciclovir Prophylaxis in Solid Organ Transplant Recipients as a Function of Weight-adjusted Ganciclovir Exposure
por: Campanella, Toni A, et al.
Publicado: (2020)

2571. Posaconazole DRT in Children; Time to Bring Out the Pill Crusher?
por: Weerdenburg, Heather L, et al.
Publicado: (2023)

Posaconazole for lobomycosis
por: Pasqualotto, Alessandro C., et al.
Publicado: (2021)

How Much Is Too Much? Exploring Pseudohyperaldosteronism in Glycyrrhizic Acid Toxicity From Chronic Licorice Root Consumption
por: Patel, Palak, et al.
Publicado: (2021)

Identification of an Alternative Glycyrrhizin Metabolite Causing Liquorice-Induced Pseudohyperaldosteronism and the Development of ELISA System to Detect the Predictive Biomarker
por: Ishiuchi, Kan'ichiro, et al.
Publicado: (2021)

1469 Posaconazole salvage treatment for invasive fungal infection : a single center experience with utilization of posaconazole oral suspension or delayed-released tablet
por: Kim, Jong Hun, et al.
Publicado: (2014)

The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population
por: Naamane, H, et al.
Publicado: (2011)

2546. Administration of Crushed Posaconazole Delayed Release Tablets Failed to Achieve Therapeutic Levels
por: Kane, Nicholas, et al.
Publicado: (2023)

358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA)
por: Cheng, Matthew P, et al.
Publicado: (2018)

Corrigendum: Identification of an alternative glycyrrhizin metabolite causing liquorice-induced pseudohyperaldosteronism and the development of ELISA system to detect the predictive biomarker
por: Ishiuchi, Kan’ichiro, et al.
Publicado: (2022)

Clinical Outcomes of the Oral Suspension vs Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Tallman, Gregory B, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

1236. Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants in the United States
por: Senders, Shelly, et al.
Publicado: (2020)

118. Feasibility of a Proactive Amoxicillin Oral Challenge Program for Inpatients with Penicillin Allergy at the Miami VAMC
por: Piazza, Michael J, et al.
Publicado: (2021)

Safety, Tolerability, and Pharmacokinetics (PK) of Posaconazole (POS) Intravenous (IV) Solution and Oral Powder for Suspension in Children With Neutropenia
por: Groll, Andreas H, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pq2f0fjfmtvc916o4hse4a7mab